US tariffs: pharma firms not planning job cuts in Switzerland
Select your language
Generated with artificial intelligence.
Listening:
US tariffs: pharma firms not planning job cuts in Switzerland
The additional investments in the US will not lead to a reduction in jobs in Switzerland. This is according to pharmaceutical giant Roche, which expects the number of employees to remain stable in the current year. The position of Novartis is similar.
“With our recent $50 billion (CHF 40.4 billion at today’s exchange rate) investment in the US, we reaffirm our commitment to the healthcare system and patients in this region,” the Basel-based company told the Keystone-SDA news agency.
+Get the most important news from Switzerland in your inbox
Reacting to an article in today’s NZZ am Sonntag about the capacity expansion in the US, Roche added that it does not foresee any impact of the investments on employees in Switzerland and other countries for now. “We have invested billions of francs in our operations in Switzerland and Europe and will continue to do so.”
The Zurich Sunday paper also mentions the other major Swiss pharmaceutical group, Novartis, claiming that it intends to produce 100% of its most important drugs entirely in the US in the future. According to the newspaper, even for Novartis, investment in the US will have no impact on production facilities outside America.
Top management meeting planned
The future of the Swiss pharmaceutical industry is now also the focus of political attention. According to the SonntagsBlick, health minister Elisabeth Baume-Schneider and economics minister Guy Parmelin are planning a meeting with the industry’s top management and are looking for a date.
More
How pharma became Switzerland’s Achilles heel in US trade talks
“The departments concerned have regular exchanges with all economic sectors, including the pharmaceutical sector. Discussions are also currently planned,” the Home Affairs ministry, headed by Baume-Schneider, told Keystone-SDA today.
What is your opinion? Join the debate:
External Content
Adapted from Italian by DeepL/ac
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
More
Holocaust survivor owes life to forger
More
With no prospects for profits, big pharma neglects new infectious diseases
More
Crime boss opens up about mob in Switzerland
More
Glencore to plead guilty to bribery charges and pay $1.5bn penalty
More
Geneva plans to pay NGO wages after US foreign aid freeze
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.